Bryan Johnson Longevity: Legal and Disclosure Obligations Explained

What Bryan Johnson Actually Takes and Why It Creates Legal Complexity

Bryan Johnson's Blueprint protocol is one of the most documented self-experimentation projects in medical history. He publishes his full stack, biomarker results, and costs online, turning personal data into a de facto public health communication. That openness is clinically interesting. It also generates real legal exposure.

The stack as of 2024 includes rapamycin (13 mg weekly), acarbose (200 mg with carbohydrate meals), metformin 500 mg (since paused after reassessment), lithium orotate, DHEA, testosterone (topical), and more than 100 additional nutraceuticals. Rapamycin is FDA-approved only for prophylaxis of organ rejection in renal transplant recipients, making any longevity application off-label under 21 U.S.C. § 396.

The Off-Label Prescribing Problem

Off-label prescribing is legal for licensed physicians. A 2006 study published in Archives of Internal Medicine estimated that 21% of all outpatient prescriptions in the U.S. Were for off-label indications, and oncology and psychiatry ran even higher [1]. The problem is not the prescribing. The problem is public promotion.

FDA regulations at 21 C.F.R. § 202.1 restrict drug manufacturers from promoting approved drugs for unapproved uses. Those rules bind companies, not individual patients. But they create a gray zone when a high-profile individual effectively markets an off-label use to millions of followers, particularly if any commercial arrangement exists with a pharmacy or supplement brand.

Rapamycin and the Evidence Gap

Rapamycin (sirolimus) extended lifespan in male and female mice by 9-14% even when started at 600 days of age in the National Institute on Aging Interventions Testing Program [2]. A 2023 phase 2 trial (PEARL, NCT04488601) tested low-dose rapamycin in healthy older adults and found no significant adverse effects at 5 mg weekly over 48 weeks [3]. That is promising. It is not FDA approval. Sharing a prescription drug protocol publicly without that distinction is where legal risk concentrates.

FTC Endorsement Guides and Influencer Disclosure

The Federal Trade Commission revised its Endorsement Guides (16 C.F.R. Part 255) in 2023 to close loopholes that had allowed social media influencers to obscure paid relationships. The updated guides require clear and conspicuous disclosure of any material connection, including equity stakes, free products, and consulting arrangements [4].

What "Material Connection" Means for Johnson

Johnson holds ownership stakes in companies whose products appear in the Blueprint stack. Blueprint Bryan Johnson LLC sells supplements directly to consumers. When Johnson posts about a product he also sells, the FTC considers that a material connection requiring disclosure. The 2023 guides specify that disclosures must appear before any promotional content, not buried at the end of a post or hidden in a profile bio [4].

A failure to disclose adequately can result in civil penalties. After the 2021 amendments to Section 5 of the FTC Act, repeat violations carry fines up to $50,120 per violation per day [5].

Testimonial Rules and Health Claims

The revised guides also tighten rules around atypical results. If Johnson shows dramatic biomarker improvements, any commercial communication tied to those results must disclose that his outcomes may not be typical. The FTC's Health Products Compliance Guidance (2022) states that health claims must be substantiated by competent and reliable scientific evidence, generally interpreted as randomized controlled trial data for therapeutic claims [5].

Supplement companies citing Johnson's protocol in their marketing inherit those obligations. A company that prints "as used by Bryan Johnson" on packaging without a material connection disclosure and without adequate clinical substantiation faces FTC enforcement risk.

FDA Dietary Supplement Regulations and the Blueprint Stack

Most of the 111 compounds in the Blueprint stack are marketed as dietary supplements, which fall under the Dietary Supplement Health and Education Act of 1994 (DSHEA). DSHEA places the burden of safety on the manufacturer, not the FDA, before marketing [6].

Structure-Function Claims vs. Disease Claims

Under 21 C.F.R. § 101.93, supplement labels may carry structure-function claims ("supports healthy aging") but not disease claims ("treats cardiovascular disease"). The line matters. A product that claims to extend lifespan or reduce biological age is edging toward a disease claim, which would require FDA approval as a drug [6].

The FDA sent warning letters to NAD precursor companies in 2022 and 2023 for making claims that crossed into disease-claim territory. Any supplement in Johnson's stack marketed with language like "reverses aging" faces the same scrutiny [7].

GMP Compliance and Third-Party Testing

Dietary supplements must be manufactured under Current Good Manufacturing Practices (cGMPs) per 21 C.F.R. Part 111 [8]. Third-party certificate-of-analysis testing by NSF International or USP Verified is not legally required but represents the standard of care clinicians reference when recommending supplements to patients. Johnson has published certificates of analysis for several Blueprint products, which is above average for the industry but does not substitute for FDA pre-market review.

State Medical Practice Laws and the Unlicensed Practice of Medicine

Johnson is not a physician. Publishing a detailed prescription drug protocol and selling companion supplements occupies a legally uncomfortable position in states that define the practice of medicine broadly.

How States Define "Practice of Medicine"

California Business and Professions Code § 2052 prohibits any person from diagnosing, treating, operating, or prescribing for any disease without a valid California license. Texas Occupations Code § 151.002 uses similar language. If a follower reads the Blueprint protocol, obtains the same prescriptions from a telehealth provider specifically because Johnson recommended it, and experiences harm, the question of whether Johnson "prescribed" enters legal debate [9].

No court has yet adjudicated that fact pattern directly. Legal scholars at the Duke Center for Health Policy have noted that the rise of biohacker influencers creates a gap between existing medical practice statutes, which were written before social media, and current reality [9].

The Physician-Patient Relationship Requirement

The American Medical Association's Code of Medical Ethics Opinion 1.1.3 states that a valid physician-patient relationship requires an adequate patient history, physical examination or equivalent, and individualized diagnosis before any prescription is issued [10]. Johnson works with a physician team that monitors his biomarkers. His followers typically do not have that infrastructure. Telehealth companies offering "Blueprint-aligned" prescription protocols should audit whether their intake processes satisfy state telemedicine standards before marketing to Johnson's audience.

Securities and Financial Disclosure Considerations

Johnson is a former founder (Braintree/Venmo, sold to PayPal for $800 million in 2013) and an active venture investor. Blueprint Bryan Johnson LLC has received outside investment. When a public figure combines a health brand with investor relations, securities law adds another disclosure layer.

SEC Rule 10b-5 and Material Misstatements

SEC Rule 10b-5 prohibits material misstatements or omissions in connection with the purchase or sale of any security [11]. If Johnson makes public claims about Blueprint's commercial prospects, product efficacy, or scientific backing that are material to investor decisions and those claims are inaccurate or incomplete, securities fraud exposure follows. This is speculative at present. It becomes concrete if Blueprint pursues a public offering or SPAC transaction.

Investor Presentation Standards

The SEC's guidance on health company disclosures (S-K Item 101) requires companies to describe the material risks of their business, including regulatory risk from FDA scrutiny of supplement claims and off-label drug promotion [11]. Any Blueprint investor deck that omits FDA and FTC regulatory risk as a material business risk would be deficient under that standard.

Clinical Research Disclosure: IRB and Informed Consent

Johnson has described his own body as "the most measured body in human history" and has collaborated with researchers publishing his data. Data collected on a human subject and published in a peer-reviewed journal requires Institutional Review Board (IRB) oversight and informed consent documentation under the Common Rule (45 C.F.R. § 46) [12].

When Self-Experimentation Requires IRB Review

The Common Rule applies when research is conducted or supported by a federal agency or conducted at an institution that has a federal-wide assurance. Private self-experimentation funded entirely outside federal channels may fall outside Common Rule jurisdiction. A 2019 analysis in the Journal of Law and the Biosciences concluded that self-experimenters who publish results without federal funding occupy a genuine regulatory gap, though journals increasingly require ethics statements regardless [12].

Published Johnson Data and Journal Ethics Policies

A 2023 paper in Nature Aging that included Johnson's longitudinal biomarker data required the authors to declare that data were collected in accordance with ethical standards [13]. The journal's policy references the Declaration of Helsinki (revised 2013), which requires that even research on oneself must protect against conflicts of interest distorting the science [13]. Johnson's commercial interest in Blueprint products is a textbook conflict that peer reviewers should scrutinize.

Metformin, Acarbose, and Off-Label Longevity Prescribing

Metformin and acarbose are FDA-approved for type 2 diabetes management. Their use in non-diabetic individuals for longevity purposes is off-label [14].

Metformin's Longevity Evidence Base

The TAME trial (Targeting Aging with Metformin, NCT03127514) is a 6-year, 3,000-participant NIH-funded RCT testing whether metformin 1,500 mg/day delays the onset of age-related diseases in adults aged 65-79 [15]. Results are expected in 2026. Until TAME reports, prescribing metformin to healthy non-diabetic adults for longevity remains evidence-light. The American Diabetes Association's 2024 Standards of Care do not endorse metformin for non-diabetic longevity use [14].

Johnson paused his own metformin use after observing data suggesting it might blunt the benefits of resistance training, consistent with a finding from a 2019 study in Aging Cell (N=53) showing that metformin reduced mitochondrial adaptations to exercise in older adults [16].

Acarbose Evidence

Acarbose extended median lifespan by 22% in male ITP mice and 5% in females at 1,000 ppm dietary concentration [17]. Human data in non-diabetic longevity use are essentially absent. Prescribing acarbose to a healthy non-diabetic adult requires the prescribing physician to document individualized clinical reasoning, because standard of care guidelines from the American Association of Clinical Endocrinology do not support this use [18].

Telehealth Companies Replicating the Blueprint Model

Several telehealth companies now offer "longevity panels" or "Blueprint-aligned" prescribing. Each inherits the same legal architecture.

State Telehealth Prescribing Laws

The Ryan Haight Online Pharmacy Consumer Protection Act (21 U.S.C. § 829) requires at least one in-person medical evaluation before a controlled substance can be prescribed via telemedicine, except during public health emergencies [19]. Rapamycin is not a controlled substance, so that restriction does not apply directly. But state medical board rules on telemedicine prescribing, which vary significantly, do apply. California's Medical Board requires that a telehealth encounter meet the same standard of care as an in-person visit before any prescription is issued [9].

Informed Consent for Off-Label Prescribing in Telehealth

The American Medical Association's guidance on informed consent (Opinion 2.1.1) requires that patients receive a clear explanation of the nature of the proposed treatment, material risks, benefits, and available alternatives before consent is valid [10]. For off-label drugs like rapamycin in longevity protocols, informed consent should specifically state that the FDA has not approved this use, that long-term human safety data are limited, and that the prescribing physician is exercising individualized clinical judgment [10].

A telehealth intake form that buries this information in a 40-page terms-of-service document likely does not satisfy AMA or state medical board standards for meaningful informed consent.

What Clinicians and Patients Should Take Away

The Blueprint protocol sits at the intersection of sincere scientific curiosity, aggressive self-quantification, and substantial commercial interest. That combination does not make it fraudulent. It makes it legally complex.

Physicians who follow Johnson's protocol should document the off-label rationale for each prescription drug in the patient's chart, obtain explicit written informed consent noting FDA approval status, and revisit that documentation when new trial data, such as TAME results in 2026, change the evidence base [15].

Patients asking for Blueprint-style prescriptions deserve a clinician who knows the difference between a mouse lifespan study and a phase 3 RCT in humans, who can explain why rapamycin's ITP data [2] do not yet translate to a prescribing recommendation, and who can order the specific biomarkers (fasting insulin, HOMA-IR, lipid particle number, high-sensitivity CRP, DEXA body composition) needed to monitor for drug effects rather than simply dispensing pills to match a protocol built for one person's unique physiology.

Baseline fasting insulin below 6 µIU/mL is a reasonable target before adding acarbose or metformin to any longevity regimen, per the American Association of Clinical Endocrinology's metabolic risk stratification framework [18].